S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
How major US stock indexes fared Friday, 4/19/2024
Stock market today: Tumbling tech stocks drag Wall Street to the finish line of another losing week
American Express profits jump 34%, helped by jump in new customers, higher spending
American Express, Fifth Third rise; Netflix, PPG Industries fall, Friday, 4/19/2024
Intuitive Surgical Stock Can Trend Much Higher This Year 
3 Magnificent Seven Stocks Outperforming the Rest
Bargain Hunting: 3 Stocks With RSIs That Scream Oversold
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
How major US stock indexes fared Friday, 4/19/2024
Stock market today: Tumbling tech stocks drag Wall Street to the finish line of another losing week
American Express profits jump 34%, helped by jump in new customers, higher spending
American Express, Fifth Third rise; Netflix, PPG Industries fall, Friday, 4/19/2024
Intuitive Surgical Stock Can Trend Much Higher This Year 
3 Magnificent Seven Stocks Outperforming the Rest
Bargain Hunting: 3 Stocks With RSIs That Scream Oversold
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
How major US stock indexes fared Friday, 4/19/2024
Stock market today: Tumbling tech stocks drag Wall Street to the finish line of another losing week
American Express profits jump 34%, helped by jump in new customers, higher spending
American Express, Fifth Third rise; Netflix, PPG Industries fall, Friday, 4/19/2024
Intuitive Surgical Stock Can Trend Much Higher This Year 
3 Magnificent Seven Stocks Outperforming the Rest
Bargain Hunting: 3 Stocks With RSIs That Scream Oversold
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
How major US stock indexes fared Friday, 4/19/2024
Stock market today: Tumbling tech stocks drag Wall Street to the finish line of another losing week
American Express profits jump 34%, helped by jump in new customers, higher spending
American Express, Fifth Third rise; Netflix, PPG Industries fall, Friday, 4/19/2024
Intuitive Surgical Stock Can Trend Much Higher This Year 
3 Magnificent Seven Stocks Outperforming the Rest
Bargain Hunting: 3 Stocks With RSIs That Scream Oversold

Compare Stocks

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Becton, Dickinson and Company stock logo
BDX
Becton, Dickinson and Company
$234.18
+0.4%
$240.00
$229.40
$287.32
$67.65B0.431.41 million shs1.27 million shs
Boston Scientific Co. stock logo
BSX
Boston Scientific
$67.33
-0.1%
$67.25
$48.35
$69.21
$98.91B0.786.38 million shs6.95 million shs
DexCom, Inc. stock logo
DXCM
DexCom
$130.71
-2.7%
$129.55
$74.75
$142.00
$50.39B1.22.98 million shs2.86 million shs
ResMed Inc. stock logo
RMD
ResMed
$178.85
+0.7%
$186.18
$132.24
$243.52
$26.31B0.671.01 million shs1.21 million shs
7 Stocks to Own Before the 2024 Election Cover

Looking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Becton, Dickinson and Company stock logo
BDX
Becton, Dickinson and Company
+0.44%-0.42%-1.55%-0.72%-9.53%
Boston Scientific Co. stock logo
BSX
Boston Scientific
-0.13%-1.09%-0.15%+10.49%+27.30%
DexCom, Inc. stock logo
DXCM
DexCom
-2.67%-3.99%-1.37%+2.69%+5.31%
ResMed Inc. stock logo
RMD
ResMed
+0.70%-3.77%-7.03%+3.66%-19.57%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Becton, Dickinson and Company stock logo
BDX
Becton, Dickinson and Company
4.7591 of 5 stars
2.43.03.34.03.32.52.5
Boston Scientific Co. stock logo
BSX
Boston Scientific
4.3295 of 5 stars
2.53.00.04.22.52.52.5
DexCom, Inc. stock logo
DXCM
DexCom
4.388 of 5 stars
1.54.00.04.73.32.53.1
ResMed Inc. stock logo
RMD
ResMed
4.8303 of 5 stars
3.41.04.24.52.61.72.5

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Becton, Dickinson and Company stock logo
BDX
Becton, Dickinson and Company
2.80
Moderate Buy$280.0019.57% Upside
Boston Scientific Co. stock logo
BSX
Boston Scientific
3.00
Buy$68.501.74% Upside
DexCom, Inc. stock logo
DXCM
DexCom
2.93
Moderate Buy$141.408.18% Upside
ResMed Inc. stock logo
RMD
ResMed
2.70
Moderate Buy$199.2011.38% Upside

Current Analyst Ratings

Latest BSX, BDX, DXCM, and RMD Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
4/15/2024
Boston Scientific Co. stock logo
BSX
Boston Scientific
Royal Bank of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOutperform ➝ Outperform$70.00 ➝ $78.00
4/10/2024
DexCom, Inc. stock logo
DXCM
DexCom
UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$153.00 ➝ $163.00
4/4/2024
Boston Scientific Co. stock logo
BSX
Boston Scientific
Evercore ISI
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOutperform ➝ Outperform$68.00 ➝ $72.00
4/3/2024
Boston Scientific Co. stock logo
BSX
Boston Scientific
Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$71.00 ➝ $79.00
4/3/2024
Boston Scientific Co. stock logo
BSX
Boston Scientific
Argus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$69.00 ➝ $80.00
4/3/2024
DexCom, Inc. stock logo
DXCM
DexCom
Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$148.00 ➝ $161.00
4/1/2024
ResMed Inc. stock logo
RMD
ResMed
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$215.00 ➝ $224.00
3/27/2024
ResMed Inc. stock logo
RMD
ResMed
Mizuho
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$215.00
3/12/2024
DexCom, Inc. stock logo
DXCM
DexCom
Royal Bank of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOutperform$165.00
3/7/2024
Boston Scientific Co. stock logo
BSX
Boston Scientific
TD Cowen
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOutperform ➝ Outperform$65.00 ➝ $77.00
2/6/2024
ResMed Inc. stock logo
RMD
ResMed
KeyCorp
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOverweight$227.00
(Data available from 4/20/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Becton, Dickinson and Company stock logo
BDX
Becton, Dickinson and Company
$19.37B3.49$20.40 per share11.48$88.92 per share2.63
Boston Scientific Co. stock logo
BSX
Boston Scientific
$14.24B6.94$2.88 per share23.41$13.33 per share5.05
DexCom, Inc. stock logo
DXCM
DexCom
$3.62B13.91$2.02 per share64.69$5.35 per share24.43
ResMed Inc. stock logo
RMD
ResMed
$4.50B5.84$8.03 per share22.26$28.11 per share6.36

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Becton, Dickinson and Company stock logo
BDX
Becton, Dickinson and Company
$1.48B$4.2255.4916.351.926.44%13.57%6.56%5/2/2024 (Confirmed)
Boston Scientific Co. stock logo
BSX
Boston Scientific
$1.59B$1.0762.9326.512.3811.19%15.99%8.87%4/24/2024 (Confirmed)
DexCom, Inc. stock logo
DXCM
DexCom
$541.50M$1.3199.7858.612.3014.95%28.31%9.74%4/25/2024 (Confirmed)
ResMed Inc. stock logo
RMD
ResMed
$897.56M$6.0529.5621.712.1519.77%23.86%14.78%4/25/2024 (Confirmed)

Latest BSX, BDX, DXCM, and RMD Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/2/2024N/A
Becton, Dickinson and Company stock logo
BDX
Becton, Dickinson and Company
$2.96N/A-$2.96N/AN/AN/A  
4/25/2024N/A
DexCom, Inc. stock logo
DXCM
DexCom
$0.27N/A-$0.27N/AN/AN/A  
4/25/2024N/A
ResMed Inc. stock logo
RMD
ResMed
$1.93N/A-$1.93N/AN/AN/A  
4/24/2024N/A
Boston Scientific Co. stock logo
BSX
Boston Scientific
$0.51N/A-$0.51N/AN/AN/A  
2/8/2024Q4 2023
DexCom, Inc. stock logo
DXCM
DexCom
$0.43$0.50+$0.07$0.38$1.02 billion$1.03 billion      
2/1/2024Q1 2024
Becton, Dickinson and Company stock logo
BDX
Becton, Dickinson and Company
$2.39$2.68+$0.29$4.40$4.73 billion$4.71 billion      
1/31/2024Q4 23
Boston Scientific Co. stock logo
BSX
Boston Scientific
$0.51$0.55+$0.04$0.76$3.59 billion$3.73 billion    
1/24/2024Q2 24
ResMed Inc. stock logo
RMD
ResMed
$1.81$1.88+$0.07$2.34$1.15 billion$1.16 billion      

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Becton, Dickinson and Company stock logo
BDX
Becton, Dickinson and Company
$3.801.62%+4.77%90.05%52 Years
Boston Scientific Co. stock logo
BSX
Boston Scientific
N/AN/AN/AN/AN/A
DexCom, Inc. stock logo
DXCM
DexCom
N/AN/AN/AN/AN/A
ResMed Inc. stock logo
RMD
ResMed
$1.921.07%+5.66%31.74%12 Years

Latest BSX, BDX, DXCM, and RMD Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
1/23/2024
Becton, Dickinson and Company stock logo
BDX
Becton, Dickinson and Company
quarterly$0.951.59%3/7/20243/8/20243/29/2024
1/24/2024
ResMed Inc. stock logo
RMD
ResMed
quarterly$0.481.12%2/7/20242/8/20243/14/2024
(Data available from 1/1/2013 forward)

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Becton, Dickinson and Company stock logo
BDX
Becton, Dickinson and Company
0.56
1.08
0.64
Boston Scientific Co. stock logo
BSX
Boston Scientific
0.44
1.32
0.82
DexCom, Inc. stock logo
DXCM
DexCom
1.18
2.84
2.48
ResMed Inc. stock logo
RMD
ResMed
0.27
3.11
1.89

Ownership

Institutional Ownership

CompanyInstitutional Ownership
Becton, Dickinson and Company stock logo
BDX
Becton, Dickinson and Company
86.97%
Boston Scientific Co. stock logo
BSX
Boston Scientific
89.07%
DexCom, Inc. stock logo
DXCM
DexCom
97.75%
ResMed Inc. stock logo
RMD
ResMed
54.98%

Insider Ownership

CompanyInsider Ownership
Becton, Dickinson and Company stock logo
BDX
Becton, Dickinson and Company
0.31%
Boston Scientific Co. stock logo
BSX
Boston Scientific
0.50%
DexCom, Inc. stock logo
DXCM
DexCom
0.41%
ResMed Inc. stock logo
RMD
ResMed
1.21%

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
Becton, Dickinson and Company stock logo
BDX
Becton, Dickinson and Company
73,000288.90 million288.01 millionOptionable
Boston Scientific Co. stock logo
BSX
Boston Scientific
48,0001.47 billion1.46 billionOptionable
DexCom, Inc. stock logo
DXCM
DexCom
9,600385.52 million383.93 millionOptionable
ResMed Inc. stock logo
RMD
ResMed
10,140147.09 million145.31 millionOptionable

BSX, BDX, DXCM, and RMD Headlines

SourceHeadline
ResMed Inc. (NYSE:RMD) Shares Sold by Everence Capital Management Inc.ResMed Inc. (NYSE:RMD) Shares Sold by Everence Capital Management Inc.
marketbeat.com - April 19 at 6:43 AM
Analysts remain high on ResMed despite potential sleep apnea benefits from GLP-1sAnalysts remain high on ResMed despite potential sleep apnea benefits from GLP-1s
massdevice.com - April 18 at 1:12 PM
ResMed (RMD) Earnings Expected to Grow: What to Know Ahead of Next Weeks ReleaseResMed (RMD) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
zacks.com - April 18 at 11:08 AM
ResMed Inc. (NYSE:RMD) Stake Raised by Mackenzie Financial CorpResMed Inc. (NYSE:RMD) Stake Raised by Mackenzie Financial Corp
marketbeat.com - April 18 at 6:31 AM
ResMed (RMD) Set to Announce Earnings on ThursdayResMed (RMD) Set to Announce Earnings on Thursday
americanbankingnews.com - April 18 at 1:58 AM
ResMed caught between two narratives: Bearish sleep apnea data and bullish analystsResMed caught between two narratives: Bearish sleep apnea data and bullish analysts
marketindex.com.au - April 18 at 1:33 AM
Tandem Investment Advisors Inc. Has $64.58 Million Stake in ResMed Inc. (NYSE:RMD)Tandem Investment Advisors Inc. Has $64.58 Million Stake in ResMed Inc. (NYSE:RMD)
marketbeat.com - April 17 at 7:32 PM
Why Eli Lilly Stock Beat the Market Today While ResMed and AdaptHealth SankWhy Eli Lilly Stock Beat the Market Today While ResMed and AdaptHealth Sank
fool.com - April 17 at 6:51 PM
Why Eli Lilly Stock Beat the Market Today While ResMed and AdaptHealth SankWhy Eli Lilly Stock Beat the Market Today While ResMed and AdaptHealth Sank
fool.com - April 17 at 6:51 PM
ResMed (NYSE:RMD) Sees Strong Trading VolumeResMed (NYSE:RMD) Sees Strong Trading Volume
marketbeat.com - April 17 at 4:53 PM
ResMed Unusual Options Activity For April 17ResMed Unusual Options Activity For April 17
benzinga.com - April 17 at 10:32 AM
Eli Lilly Pops After Weight-Loss Drug Succeeds In Sleep Apnea Test; ResMed DivesEli Lilly Pops After Weight-Loss Drug Succeeds In Sleep Apnea Test; ResMed Dives
investors.com - April 17 at 8:57 AM
Needham sees BSX, CNMD, RMD beating Street, despite medtech slow downNeedham sees BSX, CNMD, RMD beating Street, despite medtech slow down
msn.com - April 14 at 6:59 PM
ResMed Inc. (NYSE:RMD) Shares Purchased by Mirae Asset Global Investments Co. Ltd.ResMed Inc. (NYSE:RMD) Shares Purchased by Mirae Asset Global Investments Co. Ltd.
marketbeat.com - April 14 at 5:19 AM
Vaughan David Investments LLC IL Purchases New Holdings in ResMed Inc. (NYSE:RMD)Vaughan David Investments LLC IL Purchases New Holdings in ResMed Inc. (NYSE:RMD)
marketbeat.com - April 12 at 8:51 PM
Short interest in S&P 500 health stocks rises, Moderna among most shorted companies in MarchShort interest in S&P 500 health stocks rises, Moderna among most shorted companies in March
msn.com - April 12 at 2:09 PM
ResMed Inc. Forecasted to Earn Q1 2025 Earnings of $1.94 Per Share (NYSE:RMD)ResMed Inc. Forecasted to Earn Q1 2025 Earnings of $1.94 Per Share (NYSE:RMD)
americanbankingnews.com - April 12 at 2:20 AM
ResMed Inc. Forecasted to Post Q1 2025 Earnings of $1.94 Per Share (NYSE:RMD)ResMed Inc. Forecasted to Post Q1 2025 Earnings of $1.94 Per Share (NYSE:RMD)
marketbeat.com - April 11 at 7:42 AM
Zacks Research Comments on ResMed Inc.s Q3 2024 Earnings (NYSE:RMD)Zacks Research Comments on ResMed Inc.'s Q3 2024 Earnings (NYSE:RMD)
americanbankingnews.com - April 11 at 1:36 AM
Hendershot Investments Inc. Acquires Shares of 44,068 ResMed Inc. (NYSE:RMD)Hendershot Investments Inc. Acquires Shares of 44,068 ResMed Inc. (NYSE:RMD)
marketbeat.com - April 10 at 7:55 PM
Q3 2024 EPS Estimates for ResMed Inc. Lifted by Analyst (NYSE:RMD)Q3 2024 EPS Estimates for ResMed Inc. Lifted by Analyst (NYSE:RMD)
marketbeat.com - April 10 at 8:28 AM
Nisa Investment Advisors LLC Has $11.50 Million Position in ResMed Inc. (NYSE:RMD)Nisa Investment Advisors LLC Has $11.50 Million Position in ResMed Inc. (NYSE:RMD)
marketbeat.com - April 9 at 6:38 AM
ResMed Inc. (NYSE:RMD) Receives Average Recommendation of "Moderate Buy" from AnalystsResMed Inc. (NYSE:RMD) Receives Average Recommendation of "Moderate Buy" from Analysts
marketbeat.com - April 9 at 2:30 AM
New York State Teachers Retirement System Trims Stock Holdings in ResMed Inc. (NYSE:RMD)New York State Teachers Retirement System Trims Stock Holdings in ResMed Inc. (NYSE:RMD)
marketbeat.com - April 8 at 6:49 AM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

All Headlines

Company Descriptions

Becton, Dickinson and Company logo

Becton, Dickinson and Company

NYSE:BDX
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional. The BD Medical segment provides peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular access technology, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detections, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, and sharps disposal systems; IV medication safety and infusion therapy delivery systems, medication compounding workflow systems, automated medication dispensing and supply management systems, and medication inventory optimization and tracking systems; and prefillable drug delivery systems. The BD Life Sciences segment offers specimen and blood collection products; automated blood and tuberculosis culturing, molecular testing, microorganism identification and drug susceptibility, and liquid-based cytology systems, as well as rapid diagnostic assays, microbiology laboratory automation products, and plated media products; and fluorescence-activated cell sorters and analyzers, antibodies and kits, reagent systems, and solutions for single-cell gene expression analysis, as well as clinical oncology, immunological, and transplantation diagnostic/monitoring reagents and analyzers. The BD Interventional segment provides hernia and soft tissue repair, biological and bioresorbable grafts, biosurgery, and other surgical products; surgical infection prevention; peripheral intervention products; and urology and critical care products. The company was founded in 1897 and is headquartered in Franklin Lakes, New Jersey.
Boston Scientific logo

Boston Scientific

NYSE:BSX
Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system. It also provides technologies for diagnosing and treating coronary artery disease and aortic valve conditions; WATCHMAN FLX, a Left Atrial Appendage Closure Device; and implantable devices that monitor the heart and deliver electricity to treat cardiac abnormalities, such as cardioverter and cardiac resynchronization therapy defibrillators, MRI S-ICD systems, cardiac resynchronization therapy pacemakers, quadripolar LV leads, ICD leads, pacing leads, remote patient management systems, insertable cardiac monitor systems, and remote cardiac monitoring systems. In addition, the company offers diagnosis and treatment of rate and rhythm disorders of the heart; peripheral arterial and venous diseases; and products to diagnose, treat and ease forms of cancer. The company was incorporated in 1979 and is headquartered in Marlborough, Massachusetts.
DexCom logo

DexCom

NASDAQ:DXCM
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions. It has also submitted FDA review for Dexcom Stelo for people with type 2 diabetes. The company has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop blood-based or interstitial glucose monitoring products. It markets its products directly to endocrinologists, physicians, and diabetes educators. The company was incorporated in 1999 and is headquartered in San Diego, California.
ResMed logo

ResMed

NYSE:RMD
ResMed Inc. develops, manufactures, distributes, and markets medical devices and cloud-based software applications for the healthcare markets. It operates in two segments, Sleep and Respiratory Care, and Software as a Service. It offers various products and solutions for a range of respiratory disorders, including technologies to be applied in medical and consumer products, ventilation devices, diagnostic products, mask systems for use in the hospital and home, headgear and other accessories, dental devices, and cloud-based software informatics solutions to manage patient outcomes, as well as provides customer and business processes. The company also provides AirView, a cloud-based system that enables remote monitoring and changing of patients' device settings; myAir, a personalized therapy management application for patients with sleep apnea that provides support, education, and troubleshooting tools for increased patient engagement and improved compliance; U-Sleep, a compliance monitoring solution that enables home medical equipment (HME) to streamline their sleep programs; connectivity module and propeller solutions; and Propeller portal. It offers out-of-hospital software solution, such as Brightree business management software and service solutions to providers of HME, pharmacy, home infusion, orthotics, and prosthetics services; MatrixCare care management and related ancillary solutions to senior living, skilled nursing, life plan communities, home health, home care, and hospice organizations, as well as related accountable care organizations; HEALTHCAREfirst that offers electronic health record, software, billing and coding services, and analytics for home health and hospice agencies; and MEDIFOX DAN's software solutions. The company markets its products to sleep clinics, home healthcare dealers, and hospitals through a network of distributors and direct sales force. The company was founded in 1989 and is headquartered in San Diego, California.